Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Open-label phase 2/3 feasibility and safety study of intravenous 99mTc-PSMA-T4 in prostate cancer
2024-519358-35-00Phase 3Completed
- Sponsor
- National Centre for Nuclear Research
- Start
- Jan 2025
- Modality
- Antibody-Radionuclide Conjugates → Antibody Conjugates → Antibody-Based Therapeutics, Small Molecules
- Countries
- 1
01
Overview
Phase 3, open-label trial of RHN001-Dx in prostate cancer (PCa) (3 cohorts), sponsored by National Centre for Nuclear Research. Primary endpoint: Primary feasibility endpoint. Started Jan 2025; status: completed.
02
Drugs
RHN001-Dx
03
Conditions
prostate cancer (PCa)
Beyond the preview
Go deeper on 2024-519358-35-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-519358-35-00.